Highlights on nivolumab plus ipilimumab vs EXTREME in 1st-line high-risk squamous cell carcinoma of the head and neck: The CheckMate 651 study
ESMO 2021: CheckMate 651 study
Share.
Highlights on nivolumab plus ipilimumab vs EXTREME in 1st-line high-risk squamous cell carcinoma of the head and neck: The CheckMate 651 study